Skip to main content

Training Network for the Development of Bacterial ExoPolysaccharides for the treatment of Inflammatory Conditions

Objective

The essence of this proposal is to establish a collaborative training network which will develop novel immune-regulatory molecules from Bifidobacterium infantis 35624, for treatment of inflammatory diseases. A multidisciplinary team of four prestigious European partners has been assembled (SME & Coordinator - Alimentary Health Ltd (expert in developing probiotic products); Swiss Institute for Asthma and Allergy Research, (expert in immune-regulation); Vienna Institute of Biotechnology at Universität für Bodenkultur (expert in glycobiology); and University College Cork, Alimentary Pharmabiotics Centre and Department of Microbiology (expert in bioinformatics and glycobiology assembly in probiotic bacteria). Each partner will provide unique critical expertise, through knowledge, personnel and facilities which will be complementary and additive and will provide the synergistic expertise required to successfully deliver on the goal of this project and forge a long-lasting relationship. The end result: a unique opportunity for cross-sector state-of-the-art knowledge transfer and dissemination, through the identification of molecules from B. infantis 35624 with proven efficacy in the treatment of IBS and other inflammatory conditions – expected to have major commercialization, economic and health implications.
B. infantis 35624 is a commensal micro-organism, originally isolated from human gastrointestinal tissue, which has demonstrated unique properties in human clinical studies. B. infantis 35624 consumption is associated with significant improvement in the composite score for abdominal pain/discomfort, bloating/distention, and/or bowel movement difficulty compared with placebo in two appropriately designed studies. No other bacterial strain has shown significant improvement in Irritable Bowel Syndrome (IBS) symptoms. The exact mechanisms underpinning the clinical benefit are not known but modulation of the host immune response is strongly believed to play a role.

Field of science

  • /medical and health sciences/health sciences/public and environmental health/epidemics prevention/immunisation
  • /natural sciences/biological sciences/microbiology/bacteriology
  • /medical and health sciences/health sciences/inflammatory diseases

Call for proposal

FP7-PEOPLE-2011-IAPP
See other projects for this call

Funding Scheme

MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP)

Coordinator

SCHWEIZERISCHES FORSCHUNGSINSTITUT FUER HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS
Address
Promenade 35
7270 Davos Platz
Switzerland
Activity type
Research Organisations
EU contribution
€ 270 026
Administrative Contact
Liam O'mahony (Dr.)

Participants (4)

ALIMENTARY HEALTH LTD
Ireland
EU contribution
€ 317 791
Address
Kinsale Road Building 2800 Cork Airport Business Park
N/A Passage West, Co. Cork
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jennifer Roper (Dr.)
UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK
Ireland
EU contribution
€ 121 059
Address
Western Road
T12 YN60 Cork
Activity type
Higher or Secondary Education Establishments
Administrative Contact
David O'connell (Dr.)
UNIVERSITAET FUER BODENKULTUR WIEN
Austria
EU contribution
€ 207 192
Address
Gregor Mendel Strasse 33
1180 Wien
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Friedrich Altmann (Prof.)
ALIMENTARY HEALTH PHARMA DAVOS AG
Switzerland
EU contribution
€ 141 863
Address
Obere Strasse 22
7270 Davos Platz
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jennifer Roper (Dr.)